Mary L. (Nora) Disis
@DrNDisis
Followers
2K
Following
48
Statuses
1K
Director, UW Medicine Cancer Vaccine Institute. Editor in Chief, JAMA Oncology. Research: vaccines for the prevention of cancer and cancer relapse.
University of Washington
Joined February 2015
CVI Director @DrNDisis, Exec Dir @kirandhillonphd & colleagues are at #SITC2022! Grad students & postdocs interested in an exciting career in cancer vaccines & tumor immunology, we want to meet you! Discovery, translation, and clinical trials under one roof. Email: kkd@uw.edu
0
0
7
0
0
2
RT @UWCancerVaccine: We’re excited to share a new paper by CVI’s Dr. John Liao on a clinical trial for combination Pembrolizumab and low do…
0
2
0
RT @science_seattle: 👨⚕️👩⚕️ Drs. Sasha Stanton (@sestant29), Nora Disis (@DrNDisis), and fellow @UWCancerVaccine researchers found that c…
0
3
0
RT @uwmnewsroom: 5 immune response markers might predict #COVID19 patient outcomes & possibly become useful in candidate vaccine assessment…
0
14
0
RT @JackWestMD: In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCL…
0
12
0
RT @0131Liu: Thanks for my nicest colleagues! I am the best, because all of you! @UWCancerVaccine
0
2
0
Laura is an amazing scientist!
CVI’s Dr. Laura Riolobos is making a #vaccine for #liposarcoma, to help her friend & others with this rare #cancer. Read more: @UWMedicine #SarcomaAwareness #CureSarcoma #Sarcoma #Research
0
2
7
Pembrolizumab After Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer New at @JAMA Onc-ablation of oligometastatic NSCLC followed by immune checkpoint: OS at 12 mo-90%. Novel and promising application of immune checkpoint inhibition.
0
4
19
Regulatory roles of IL-10–producing human follicular T cells
0
1
3
I'm a fan of testing early. Immune therapy more be more effective with less bulky disease.
Fascinating. Test early or late in the disease course? Seems like later could pick up more candidates for IO
0
2
7
RT @guptaarjun90: Patient page on #CIPN (Chemo Induced Peripheral Neuropathy), in @JAMAOnc w/ @TimothyJBrownMD @ramsedhom
#QOL matters. Ca…
0
30
0
Thank you UW CVI #ImmunoOnc19 @UWCancerVaccine
Just a reminder that you can’t top @thenci ‘s @gulleyj1 for #immunotherapy on Twitter 😉. Thank you also @DrChoueiri @DrNDisis @asco @sitc @PGrivasMDPhD @xiaoweimd @CMAnnunziata @phase1oncomd et al for a great #ImmunoOnc19.
0
0
1
VERY IMPORTANT COMMENT!!! #ImmunoOnc19 @UWCancerVaccine
if presenters include NCT trial number 1) attendees can look at some of the perameters of trial (e.g. dosing) 2) clinicians can find out that this presentation of findings exist 3) if there is a related trial (or an open arm), patients can find out more about trial. #ImmunoOnc19
0
1
6
Dr. Kandalaft points out that there are many types of antigens that can be used for vaccination, neo antigens of all types- not just point mutations. Target epigenetic changes, phospho Ag...etc. #ImmunoOnc19 @UWCancerVaccine
0
3
8
Dr. Palucka highlights the importance of DC in mediating response to ICI. Recent Immunity paper implicated IFN-g and IL-12 in T cell DC cross-talk. #ImmunoOnc19 @UWCancerVaccine
1
2
4
Dendritic cells are the most important antigen presenting cells for stimulating T-cell responses to cancer. Nobel Prize winning tumor immunologist Dr. Ralph Steinman was honored for his work in this area. #ImmunoOnc19
0
1
15
Dr. Palucka highlights the issues associated with mutated antigen vaccines; the mutations have to be presented enodogenously in the patients MHC. Most are not. #Immunotherapy #immunoonc19 @UWCancerVaccine
0
3
11
@DrBetofMDPhD @DrChoueiri @DrRoyHerbstYale Key question on risk. Would depend on what we now know about the AE, the patient population, etc. The original AE with ICI begged that question A LOT- now we know how to treat effectively and catch early #ImmunoOnc19
0
1
1